JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Deferiprone (tradename Ferriprox) is novel, potent and orally bioactive iron-chelating drug used for transfusional iron overload clinically. It was approved in 1994 for treating thalassaemia major in Europe and Asia. On October 14, 2011, it was approved for use in the US under the FDAA’s accelerated approval program. Deferiprone binds to iron and removes it from the blood stream. Deferiprone is used to treat iron overload caused by blood transfusions in people with certain hereditary red blood cell disorders (thalassemia syndrome).
References: Drug Saf. 2003; 26(8):553-584.
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!